Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2025)

Q32 Bio (QTTB) has 9 years of Liabilities and Shareholders Equity data on record, last reported at $61.8 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 33.09% year-over-year to $61.8 million; the TTM value through Dec 2025 reached $264.7 million, down 44.08%, while the annual FY2025 figure was $61.8 million, 33.09% down from the prior year.
  • Liabilities and Shareholders Equity reached $61.8 million in Q4 2025 per QTTB's latest filing, up from $57.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $311.0 million in Q1 2022 and bottomed at $47.1 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $165.8 million, with a median of $160.8 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 79.4% in 2023, then surged 96.21% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $211.7 million in 2021, then increased by 7.91% to $228.5 million in 2022, then tumbled by 79.4% to $47.1 million in 2023, then surged by 96.21% to $92.3 million in 2024, then tumbled by 33.09% to $61.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $61.8 million in Q4 2025, $57.8 million in Q3 2025, and $66.1 million in Q2 2025.